Key Development On August 26, 2026, global oncology biopharmaceutical company BeOne Medicines announced that the U.S. Food and Drug Administration... Read more
Upper GI Immuno-Oncology Milestone: US FDA Approves BeOne Medicines’ TEVIMBRA® (Tislelizumab) Regimen Combined with ZIIHERA® (Zanidatamab) and Chemotherapy in First-Line HER2-Positive GEA, Delivering 26.4 Months Median Overall Survival
27/08/2026
Published by Pharma Biz
